Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's disease

Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, leading to se...

Full description

Saved in:
Bibliographic Details
Published in:Stem cell research & therapy 2024-12, Vol.15 (1), p.476-14
Main Authors: Ekrani, Seyedeh Toktam, Mahmoudi, Mahmoud, Haghmorad, Dariush, Kheder, Ramiar Kamal, Hatami, Alireza, Esmaeili, Seyed-Alireza
Format: Article
Language:English
Subjects:
Animals
Cell Differentiation
Development and progression
Diseases
Dopaminergic Neurons - metabolism
Dopaminergic Neurons - pathology
Epigenetic inheritance
Humans
Medical research
Medicine, Experimental
Mesenchymal Stem Cell Transplantation - methods
Mesenchymal stem cells
Mesenchymal Stem Cells - cytology
Mesenchymal Stem Cells - metabolism
MSCs manipulation
Neurons
Parkinson Disease - therapy
Parkinson's disease
Review
Stem cell therapy
Stem cells
Transplantation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, leading to severe motor and non-motor complications in patients. As current treatments are unable to halt the progression of neuronal loss and dopamine degradation, MSC therapy has emerged as a highly promising strategy for PD treatment. This promise is due to MSCs' unique properties compared to other types of stem cells, including self-renewal, differentiation potential, immune privilege, secretion of neurotrophic factors, ability to improve damaged tissue, modulation of the immune system, and lack of ethical concerns. MSCs have been employed in numerous pre-clinical and clinical studies for PD treatment with promising results. However, certain aspects of their efficacy in treating PD may benefit from various genetic and epigenetic modifications. In this review article, we assess these approaches to improving MSCs for specialized treatment of PD.
ISSN:1757-6512
1757-6512
DOI:10.1186/s13287-024-04073-9